• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Inovio Biomedical Licenses Electroporation Delivery Technology to Leading U.S. Government Contractor, Advanced BioScience Laboratories, Inc.

Posted on: Tuesday, 27 May 2008, 06:00 CDT

Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced today that it has entered into a license agreement with Advanced BioScience Laboratories, Inc. (ABL) so that ABL may provide advanced electroporation delivery of DNA vaccines for its research uses. The license will permit ABL, based in Kensington, Maryland, to conduct certain internal research on DNA vaccines delivered using electroporation and to offer electroporation delivery of DNA vaccines as a service for its research customers. Inovio will receive a royalty on such services.

Phil Markham, Ph.D., Scientific Director of ABL, said: "We have used electroporation, like the results being produced using this technology, and feel it is an important tool in vaccine development. Clients have been requesting electroporation technology and we look forward to being able to provide this cutting edge tool and expertise as a service for customers."

Avtar Dhillon, MD, president and CEO of Inovio, said: "We are pleased to enter into a license agreement with ABL, one of the leading providers of contract vaccine development services for the US government. We believe this license may help enable the early development of a number of vaccines designed to elicit strong T-cell responses, which are thought to be needed to control a number of chronic infectious diseases, such as HIV and cancer."

About Advanced BioScience Laboratories, Inc.

ABL is dedicated to conducting research and providing resources to develop and evaluate vaccines, therapeutics and diagnostics for infectious agents for the biomedical community. ABL is a highly skilled contract research organization (CRO) having extensive experience working with government, commercial, and other groups. ABL is committed to delivering quality services that advance HIV and infectious disease research for the public good. ABL can help with all aspects of product development including; basic research, vaccine or product design, animal models to include immunomonitoring, cGMP manufacturing of biologics for phase I and II clinical trials, and many other services. To find out more about ABL, please visit the company's website at www.ablinc.com.

About Inovio Biomedical Corporation

Inovio Biomedical (AMEX: INO) is focused on developing multiple DNA-based immunotherapies and DNA vaccines. Inovio is a leader in developing human applications of electroporation using brief, controlled electrical pulses to increase cellular uptake of a useful biopharmaceutical. Human data has shown that Inovio's electroporation-based DNA delivery technology can significantly increase gene expression and immune responses from DNA vaccines. Immunotherapy partners include Merck, Wyeth, Vical, University of Southampton, Moffitt Cancer Center, the U.S. Army, National Cancer Institute, and International Aids Vaccine Initiative. Inovio's technology is protected by an extensive patent portfolio covering in vivo electroporation. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our plans to develop our electroporation drug and gene delivery technology. Actual events or results may differ from our expectations as a result of a number of factors, including the uncertainties inherent in clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications and that results from one study may not necessarily be reflected or supported by the results of other similar studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of Inovio's technology as a delivery mechanism, the availability or potential availability of alternative therapies or treatments for the conditions targeted by Inovio or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that Inovio and its collaborators hope to develop, evaluation of potential opportunities, issues involving patents and whether they or licenses to them will provide Inovio with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether Inovio can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2007, our 10-Q for the three months ended March 31, 2008 and other regulatory filings from time to time. There can be no assurance that any product in our product pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proved accurate.

Source: Business Wire

More News in this Category